News and updates
Dutch scientists propose algorithm to keep drugs affordable and accessible
The paper, titled ‘Sustainability and affordability of cancer drugs: a novel pricing model’ and written by Professor Carin Uyl-de Groot and Professor Bob Lӧwenberg from Erasmus University Rotterdam in the Netherlands, proposes an algorithm that should be used to determine innovative drug prices with ‘a maximum level of transparency’.
Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopeni…
111 hematologists from 31 countries met in Barcelona for a three-day scientific meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis.
FP9 recommendations BioMed Alliance
With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research. In a recent position paper, the alliance makes the case for increased funding for basic, clinical and translational research and for the development of a long-term vision and strategy involving the creation of a European Council for Health Research.
Two genes cooperate to trigger leukemia development
Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof. Jan Cools of the VIB-KU Leuven Center for Cancer Biology who have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of the blood.
2018’s Sjöberg Prize awarded for unique treatment that cures a once fatal cancer
Dr. Zhu Chen, Dr. Anne Dejean and Dr. Hugues de Thé will be awarded the Sjöberg Prize 2018 for their work on how acute promyelocytic leukemia (APL) could be cured based on arsenic and retinoic acid.
EU funding crucial in allowing medical researchers across member states to colla…
In an article published in Science|Business, Prof.
The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online
The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online.
EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies
In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.
EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Th…
The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam,…
Myeloproliferative neoplasms better understood through scientific meeting
The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.
Renew your EHA membership
EHA members will have the chance to renew their membership with the association from today, November 14, 2017.
Key messages of the 22nd Congress of EHA brought to the Middle East and North Af…
The second edition of the Highlights of Past EHA (HOPE) brought the key messages of the 22nd Congress of EHA to the Cairo, Egypt in September 2017.
HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcom…
HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using…
Last chance: special EAPM2017 registration offer for EHA members
EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017. The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved...
PROFILE Bootcamp in Entrepreneurial Innovation in Orphan Diseases, October 23-25…
Breaking innovations in rare diseases are at the centre of this PROFILE Bootcamp, which brings together junior & senior researchers, clinicians, pharmaceutical industry and policymakers.